E Fund Management Co. Ltd. Sells 5,785 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

E Fund Management Co. Ltd. trimmed its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 55.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,668 shares of the biopharmaceutical company’s stock after selling 5,785 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Agios Pharmaceuticals were worth $201,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 0.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 314 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Agios Pharmaceuticals by 1.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000 after acquiring an additional 540 shares during the period. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals during the second quarter worth about $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals in the second quarter worth about $40,000. Finally, Federated Hermes Inc. increased its stake in shares of Agios Pharmaceuticals by 9.0% during the second quarter. Federated Hermes Inc. now owns 13,394 shares of the biopharmaceutical company’s stock valued at $578,000 after purchasing an additional 1,108 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have recently commented on AGIO shares. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, August 5th. Royal Bank of Canada restated an “outperform” rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. JPMorgan Chase & Co. restated a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Finally, The Goldman Sachs Group upped their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $51.33.

Insider Transactions at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $47.38 on Friday. Agios Pharmaceuticals, Inc. has a one year low of $19.80 and a one year high of $50.35. The business’s fifty day moving average is $45.63 and its 200 day moving average is $38.98. The stock has a market capitalization of $2.69 billion, a PE ratio of -7.50 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The company had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. During the same quarter in the prior year, the firm earned ($1.51) earnings per share. The business’s revenue was up 28.4% compared to the same quarter last year. As a group, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -4.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.